KyleESmootMD

Neurology • Portland, OR

Hospital/Neurohospitalist

Physician

Join to view full profile

Dr. Smoot is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Smoot's full profile

Already have an account?

Office
9427 SW Barnes Rd
Ste 595
Portland, OR 97225
Phone+1 503-216-1060

Fax+1 503-216-1066

Education & Training

Oregon Health & Science University (OHSU Health)Residency, Neurology, 2000 - 2004
University of Cincinnati College of MedicineClass of 2000

Certifications & Licensure

OR State Medical License 2003 - 2025
WA State Medical License 2004 - 2008
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Measurement of Relaxin Peptide in Multiple Sclerosis (MS) Start of enrollment: 2013 Sep 20
Completed
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) Start of enrollment: 2016 Dec 01
Terminated
Phase 3
Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab Start of enrollment: 2017 Jun 01
Completed
A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2) Start of enrollment: 2019 Jul 22
Active, not recruiting
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Impact of oral melatonin supplementation on urine and serum melatonin concentrations and quality-of-life measures in persons with relapsing multiple sclerosis.
Kyle Smoot, Tiffany Gervasi-Follmar, Horia Marginean, Chiayi Chen, Stanley Cohan
Multiple Sclerosis and Related Disorders. 2024-10-01
Comparing the Risk of Infusion-Related Reactions and Tolerability in Patients Given Cetirizine or Diphenhydramine Prior to Ocrelizumab Infusion (PRECEPT).
Kyle Smoot, Horia Marginean, Tiffany Gervasi-Follmar, Chiayi Chen
Medicina. 2024-04-19
1 citations
Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE).
Kyle Smoot, Horia Marginean, Tiffany Gervasi-Follmar, Chiayi Chen, Pavle Repovic
Multiple Sclerosis. 2023-07-01

Press Mentions

Report: Flag Football May Not Be Safer for KidsFebruary 20th, 2017
Think Flag Football Is Safer Than Tackle Football? Study Says Guess Again — 8 Key Takeaways FeaturedFebruary 17th, 2017
Expert Available to Discuss Higher Risk of Injury in Youth Flag Football Compared to Youth Tackle FootballFebruary 16th, 2017